Abstract Polymerase theta (Pol θ) is a DNA repair factor that has drawn much recent interest as a target for cancer therapy, since its inhibition is well-tolerated in most cells but is lethal in cancers deficient in breast cancer-associated (BRCA) genes (“synthetic lethality”). Its normal biological functions, as well as how these functions change in BRCA-deficient cancers, are only recently becoming clear, however. We review here recent progress in our understanding of the cellular regulatory mechanisms at work in determining if Pol θ sees DNA damage. At the molecular scale Pol θ then must notably see and repair diverse classes of damage, including (at least) conventional double strand breaks (made by e.g. ionizing radiation), as well as several types of damage associated with replication stress. We speculate on the mechanisms that could explain this flexibility.
Polymerase θ—what does it see, and why does it matter for cancer therapy?
Dale A. Ramsden,Gaorav P. Gupta
Published 2025 in NAR Cancer
ABSTRACT
PUBLICATION RECORD
- Publication year
2025
- Venue
NAR Cancer
- Publication date
2025-10-07
- Fields of study
Biology, Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-51 of 51 references · Page 1 of 1
CITED BY
- No citing papers are available for this paper.
Showing 0-0 of 0 citing papers · Page 1 of 1